Natalie Karam

Cooley advised the underwriters in Sagimet Biosciences’ $112.5 million follow-on offering. Goldman Sachs, TD Cowen and Leerink Partners acted as joint book-running managers for the offering. JMP Securities is acting as lead manager for the offering. Sagimet Biosciences’ is a clinical-stage biopharmaceutical company developing novel fatty acid synthase inhibitors designed to target dysfunctional metabolic pathways in diseases resulting from the overproduction of the fatty acid palmitate. Partners John McKenna, Natalie Karam and Denny Won led the Cooley team.

Cooley advised the underwriters in the upsized initial public offering of Sagimet Biosciences, a clinical-stage biotechnology company, at $85 million.

Cooley advised Ionis Pharmaceuticals, a biotechnology company, in its $575 million aggregate principal amount of convertible senior notes.

Cooley advised NVIDIA on its registered debt offering of $5 billion aggregate principal amount of investment grade senior unsecured notes. The offering consisted of $1.25 billion aggregate principal amount of 0.309% notes due 2023; $1.25 billion aggregate principal amount of 0.584% notes due 2024; $1.25 billion aggregate principal amount of 1.550% notes due 2028; and $1.25 billion aggregate principal amount of 2.000% notes due 2031. Partners Michael Tollini, Mischi a Marca, Jason Savich, Eric Jensen and John McKenna led the Cooley team advising NVIDIA.

Cooley advised Coupang, one of Asia’s largest ecommerce companies, on its $4.55 billion initial public offering of 130 million shares of Class A common stock, including 30 million shares sold by selling stockholders. In addition, Cooley advised Coupang on its $1 billion credit line by a syndicate of lenders. Lawyers Eric Jensen, Calise Cheng and Natalie Karam led the global Cooley team advising Coupang on its IPO, which is the biggest IPO in the US this year and one of the top 25 listings of all time based on deal size. Patrick Flanagan led the Cooley team advising on the credit line.